you are here: HomeNewsBiocon
biocon
Jump to
1508 Results Found
  • Kiran Mazumdar Shaw of Biocon tests positive for COVID-19 Aug 18, 2020 12:08 AM IST

    Kiran Mazumdar Shaw of Biocon tests positive for COVID-19

    Biocon is one of the companies looking to create a vaccine to fight COVID-19

  • Aim to list Biocon Biologics on capital markets by 2023: CFO MB Chinappa Aug 03, 2020 12:58 PM IST

    Aim to list Biocon Biologics on capital markets by 2023: CFO MB Chinappa

    Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.

  • Tata Capital to invest Rs 225 crore in Biocon Biologics for minority stake Jul 31, 2020 12:25 PM IST

    Tata Capital to invest Rs 225 crore in Biocon Biologics for minority stake

    The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion

  • Neutral Biocon; target of Rs 450: Motilal Oswal Jul 28, 2020 12:11 PM IST

    Neutral Biocon; target of Rs 450: Motilal Oswal

    Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 450 in its research report dated July 25, 2020.

  • Biocon share price falls 3% after Health Ministry gives a pass to its COVID-19 drug Jul 27, 2020 01:07 PM IST

    Biocon share price falls 3% after Health Ministry gives a pass to its COVID-19 drug

    A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19, sources said.

  • Pharma: Trump’s executive orders may possibly provide better market access opportunities Jul 27, 2020 11:43 AM IST

    Pharma: Trump’s executive orders may possibly provide better market access opportunities

    Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare

  • Health ministry decides against including Itolizumab in clinical management protocol for COVID-19 Jul 26, 2020 04:40 PM IST

    Health ministry decides against including Itolizumab in clinical management protocol for COVID-19

    Considering the unmet medical needs in COVID-19, Itolizumab, an already approved drug of Biocon used for treating psoriasis, was approved for "restricted emergency use" in the treatment of coronavirus by the DCGI recently.

  • Buy Biocon; target of Rs 490: ICICI Direct Jul 26, 2020 01:04 PM IST

    Buy Biocon; target of Rs 490: ICICI Direct

    ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 490 in its research report dated July 24, 2020.

  • Biocon Consolidated June 2020 Net Sales at Rs 1,671.30 crore, up 14.01% Y-o-Y Jul 24, 2020 01:05 PM IST

    Biocon Consolidated June 2020 Net Sales at Rs 1,671.30 crore, up 14.01% Y-o-Y

  • Biocon Standalone June 2020 Net Sales at Rs 520.70 crore, up 8.3% Y-o-Y Jul 24, 2020 01:05 PM IST

    Biocon Standalone June 2020 Net Sales at Rs 520.70 crore, up 8.3% Y-o-Y

  • Biocon share price falls 2% on June quarter numbers Jul 24, 2020 10:31 AM IST

    Biocon share price falls 2% on June quarter numbers

    The company's revenue from operations rose 15 percent to Rs 1,671 crore versus Rs 1,459 crore.

  • Biocon Biologics partners with Voluntis for digital therapeutics for diabetics patients Jul 21, 2020 11:30 AM IST

    Biocon Biologics partners with Voluntis for digital therapeutics for diabetics patients

    The licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis will allow Biocon Biologics to offer therapeutic product 'Insulia' to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement.

  • Biocon to launch COVID-19 drug; stock jumps 5% Jul 14, 2020 11:27 AM IST

    Biocon to launch COVID-19 drug; stock jumps 5%

    Biocon said the approval of Itolizumab, from the DCGI, is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi.

  • Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vial Jul 13, 2020 05:15 PM IST

    Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vial

    Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications, Biocon had earlier said in a regulatory filing.

  • Itolizumab is an ideal candidate for treating 'cytokine storm' in COVID-19 patients: Kiran Mazumdar Shaw Jul 11, 2020 05:01 PM IST

    Itolizumab is an ideal candidate for treating 'cytokine storm' in COVID-19 patients: Kiran Mazumdar Shaw

    DCGI has approved to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19, Biocon said in a release.

  • Biocon lines up Rs 1,500 crore capex for the current fiscal Jul 02, 2020 06:25 PM IST

    Biocon lines up Rs 1,500 crore capex for the current fiscal

    We expect capex (capital expenditure) spends to be $200 million in 2020-21, split equally between small molecules and the biosimilars businesses, Mittal said..

  • Biocon ties up with DKSH for distribution of seven products in Singapore, Thailand Jun 22, 2020 10:55 AM IST

    Biocon ties up with DKSH for distribution of seven products in Singapore, Thailand

    Biocon Pharma Ltd, a subsidiary of the bio-tech firm, and DKSH Business Unit Healthcare, have inked an agreement in this regard, Biocon Ltd said in a statement.

  • Quant Pick - Biocon; ICICI Direct Jun 18, 2020 06:10 PM IST

    Quant Pick - Biocon; ICICI Direct

    According to ICICI Direct, The pharma space has shown significant resilience in the last couple of weeks amid broader market volatility.

  • Biocon shares gain 2% on USFDA nod for insulin glargine injection Jun 12, 2020 11:04 AM IST

    Biocon shares gain 2% on USFDA nod for insulin glargine injection

    Biocon and Mylan N.V. announced that the US Food and Drug Administration has approved the New Drug Application for Semglee (insulin glargine injection) in vial and pre-filled pen presentations

  • Kiran Mazumdar Shaw named EY World Entrepreneur Of The Year 2020 Jun 05, 2020 07:39 AM IST

    Kiran Mazumdar Shaw named EY World Entrepreneur Of The Year 2020

    Shaw, 67, founded Bangalore-based Biocon Limited in 1978 with just two employees and currently leads the company that is now worth close to Rs 50,000 crore by market-cap and employs more than 11,000 people.

  • COVID-19 curve unlikely to flatten anytime soon: Kiran Mazumdar-Shaw Jun 02, 2020 03:58 PM IST

    COVID-19 curve unlikely to flatten anytime soon: Kiran Mazumdar-Shaw

    Shaw added that the focus was needed more on flattening the death curve than the infection curve.

  • Biocon share price up 2% on favourable ruling from US PTAB Jun 01, 2020 09:48 AM IST

    Biocon share price up 2% on favourable ruling from US PTAB

    The PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.

  • Biocon gains on DCGI approval for use of CytoSorb to treat critical COVID-19 patients May 27, 2020 11:23 AM IST

    Biocon gains on DCGI approval for use of CytoSorb to treat critical COVID-19 patients

    Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older.

  • Biocon Consolidated March 2020 Net Sales at Rs 1,581.00 crore, up 3.41% Y-o-Y May 21, 2020 09:16 AM IST

    Biocon Consolidated March 2020 Net Sales at Rs 1,581.00 crore, up 3.41% Y-o-Y

  • Buy Biocon; target of Rs 390: ICICI Direct May 18, 2020 05:00 PM IST

    Buy Biocon; target of Rs 390: ICICI Direct

    ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 390 in its research report dated May 18, 2020.

Sections